Loading…

Intensifying approaches to address clinical inertia among cardiovascular disease risk factors: A narrative review

Clinical inertia, the absence of treatment initiation or intensification for patients not achieving evidence-based therapeutic goals, is a primary contributor to poor clinical outcomes. Effectively combating clinical inertia requires coordinated action on the part of multiple representatives includi...

Full description

Saved in:
Bibliographic Details
Published in:Patient education and counseling 2022-12, Vol.105 (12), p.3381-3388
Main Authors: Lewinski, Allison A., Jazowski, Shelley A., Goldstein, Karen M., Whitney, Colette, Bosworth, Hayden B., Zullig, Leah L.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinical inertia, the absence of treatment initiation or intensification for patients not achieving evidence-based therapeutic goals, is a primary contributor to poor clinical outcomes. Effectively combating clinical inertia requires coordinated action on the part of multiple representatives including patients, clinicians, health systems, and the pharmaceutical industry. Despite intervention attempts by these representatives, barriers to overcoming clinical inertia in cardiovascular disease (CVD) risk factor control remain. We conducted a narrative literature review to identify individual-level and multifactorial interventions that have been successful in addressing clinical inertia. Effective interventions included dynamic forms of patient and clinician education, monitoring of real-time patient data to facilitate shared decision-making, or a combination of these approaches. Based on findings, we describe three possible multi-level approaches to counter clinical inertia – a collaborative approach to clinician training, use of a population health manager, and use of electronic monitoring and reminder devices. To reduce clinical inertia and achieve optimal CVD risk factor control, interventions should consider the role of multiple representatives, be feasible for implementation in healthcare systems, and be flexible for an individual patient’s adherence needs. Representatives (e.g., patients, clinicians, health systems, and the pharmaceutical industry) could consider approaches to identify and monitor non-adherence to address clinical inertia. •Combating clinical inertia requires coordinated action among multiple representatives.•Interventions to reduce clinical inertia should be flexible and aligned with an individual patient’s behaviors.•Involving non-physicians (e.g., nurses, pharmacists) can improve treatment initiation and/or intensification.•Clinical reminders and/or real-time data facilitates decision-making to address clinical inertia.
ISSN:0738-3991
1873-5134
DOI:10.1016/j.pec.2022.08.005